Eric Kirk, MD
Nephrology · Wilmington, NCNPI 1154530087
Payments from drug & device makers
Across 174 payments — averaging $9667.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1.2M
- Vertex$368K
- Bayer$63K
- Astrazeneca UK Limited$37K
- Eli Lilly$13K
- Gilead$9K
- plus $1K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $1,191,136 |
| Vertex | 9 | $367,558 |
| Bayer | 66 | $63,285 |
| Astrazeneca UK Limited | 1 | $37,470 |
| Eli Lilly | 1 | $12,695 |
| Gilead | 1 | $8,500 |
| Nxstage Medical, Inc. | 2 | $260 |
| Otsuka America Pharmaceutical, Inc. | 11 | $214 |
| Lilly USA, LLC | 7 | $113 |
| Bard Peripheral Vascular, Inc. | 1 | $105 |
| Amgen(2 entities) | 5 | $91 |
| Akebia Therapeutics Inc | 5 | $84 |
| Vifor Pharma, Inc. | 6 | $83 |
| Mallinckrodt Hospital Products Inc. | 4 | $80 |
| Boehringer Ingelheim | 4 | $76 |
| GSK | 3 | $57 |
| Calliditas Therapeutics US Inc. | 3 | $54 |
| Travere Therapeutics, Inc. | 5 | $50 |
| Fresenius USA Marketing, Inc. | 2 | $35 |
| OPKO Pharmaceuticals, LLC | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Novartis | 1 | $25 |
| Boston Scientific | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Aurinia Pharma U.S., Inc. | 1 | $14 |
How this compares
$1,682,090 in reported general payments places this provider in the 95th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Wilmington
- Douglas LinfertWilmington$477K
- Brian DonnerWilmington$189K
- James McCabeWilmington$56K
- Derrick RobinsonWilmington$35K
- Jonathan WoodsWilmington$32K
- Robert MooreWilmington$27K
- Daniel EdmonstonDurham$9.9M
- Gregory GreenwoodWinston-Salem$4.1M
- Barry FreedmanWinston Salem$3.5M
- Manuel MonteroNew Bern$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.